Does the media favor AVXL or XNCR?

In the previous week, Xencor had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Xencor and 1 mentions for Anavex Life Sciences. Xencor's average media sentiment score of 0.50 beat Anavex Life Sciences' score of 0.00 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AVXL or PHAR?

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 1 articles in the media. Anavex Life Sciences' average media sentiment score of 0.00 equaled Pharming Group'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MGTX or AVXL?

In the previous week, MeiraGTx had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for MeiraGTx and 1 mentions for Anavex Life Sciences. MeiraGTx's average media sentiment score of 0.87 beat Anavex Life Sciences' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AMPH or AVXL?

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 2 mentions for Amphastar Pharmaceuticals and 1 mentions for Anavex Life Sciences. Amphastar Pharmaceuticals' average media sentiment score of 0.45 beat Anavex Life Sciences' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AVXL or ETON?

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.00 beat Eton Pharmaceuticals' score of -0.05 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Anavex Life Sciences (AVXL) Competitors

$2.64 +0.06 (+2.13%)

As of 09:55 AM Eastern

Compare

AVXL vs. XNCR, PHAR, MGTX, AMPH, and ETON

Should you buy Anavex Life Sciences stock or one of its competitors? MarketBeat compares Anavex Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anavex Life Sciences include Xencor (XNCR), Pharming Group (PHAR), MeiraGTx (MGTX), Amphastar Pharmaceuticals (AMPH), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.

How does Anavex Life Sciences compare to Xencor?

Anavex Life Sciences (NASDAQ:AVXL) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Anavex Life Sciences has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Xencor	$125.58M	8.55	-$91.92M	-$2.29	N/A

Anavex Life Sciences presently has a consensus target price of $21.33, suggesting a potential upside of 709.61%. Xencor has a consensus target price of $24.50, suggesting a potential upside of 69.15%. Given Anavex Life Sciences' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

31.6% of Anavex Life Sciences shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Xencor had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Xencor and 1 mentions for Anavex Life Sciences. Xencor's average media sentiment score of 0.50 beat Anavex Life Sciences' score of 0.00 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anavex Life Sciences has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Xencor has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Anavex Life Sciences has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Xencor	-177.10%	-28.77%	-20.52%

Summary

Anavex Life Sciences beats Xencor on 8 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Pharming Group?

Anavex Life Sciences (NASDAQ:AVXL) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Pharming Group has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Pharming Group	$369.49M	2.49	$2.85M	$0.16	81.34

Anavex Life Sciences currently has a consensus price target of $21.33, suggesting a potential upside of 709.61%. Pharming Group has a consensus price target of $38.33, suggesting a potential upside of 194.53%. Given Anavex Life Sciences' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pharming Group has a net margin of 3.30% compared to Anavex Life Sciences' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Pharming Group	3.30%	4.64%	2.55%

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Anavex Life Sciences has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 1 articles in the media. Anavex Life Sciences' average media sentiment score of 0.00 equaled Pharming Group'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pharming Group beats Anavex Life Sciences on 7 of the 11 factors compared between the two stocks.

How does Anavex Life Sciences compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Anavex Life Sciences has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	13.70	-$114.20M	-$1.48	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

MeiraGTx has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

In the previous week, MeiraGTx had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for MeiraGTx and 1 mentions for Anavex Life Sciences. MeiraGTx's average media sentiment score of 0.87 beat Anavex Life Sciences' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx presently has a consensus target price of $25.83, indicating a potential upside of 114.56%. Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 709.61%. Given Anavex Life Sciences' higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Anavex Life Sciences has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Anavex Life Sciences' return on equity of -38.76% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Summary

MeiraGTx and Anavex Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Anavex Life Sciences compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Amphastar Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Anavex Life Sciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Amphastar Pharmaceuticals has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.25	$98.09M	$1.66	12.27
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Amphastar Pharmaceuticals presently has a consensus target price of $24.00, indicating a potential upside of 17.86%. Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 709.61%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 2 mentions for Amphastar Pharmaceuticals and 1 mentions for Anavex Life Sciences. Amphastar Pharmaceuticals' average media sentiment score of 0.45 beat Anavex Life Sciences' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amphastar Pharmaceuticals beats Anavex Life Sciences on 11 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Eton Pharmaceuticals?

Anavex Life Sciences (NASDAQ:AVXL) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Anavex Life Sciences has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anavex Life Sciences has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Eton Pharmaceuticals has higher revenue and earnings than Anavex Life Sciences. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Eton Pharmaceuticals	$79.95M	11.37	-$4.60M	-$0.07	N/A

Anavex Life Sciences currently has a consensus price target of $21.33, suggesting a potential upside of 709.61%. Eton Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 23.51%. Given Anavex Life Sciences' higher probable upside, research analysts clearly believe Anavex Life Sciences is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.00 beat Eton Pharmaceuticals' score of -0.05 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eton Pharmaceuticals beats Anavex Life Sciences on 7 of the 13 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVXL vs. The Competition

Export

Metric	Anavex Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$243.44M	$3.45B	$6.44B	$12.30B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-5.71	19.75	24.65	23.99
Price / Sales	N/A	331.95	535.11	118.14
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.40	8.29	10.70	6.50
Net Income	-$46.38M	$23.85M	$3.56B	$336.88M
7 Day Performance	-1.31%	2.87%	0.94%	-0.16%
1 Month Performance	-2.04%	2.19%	0.35%	0.76%
1 Year Performance	-72.44%	55.48%	29.67%	28.49%

Anavex Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVXL Anavex Life Sciences	1.5863 of 5 stars	$2.64 +2.1%	$21.33 +709.6%	-72.2%	$243.44M	N/A	N/A	40	News Coverage
XNCR Xencor	1.7207 of 5 stars	$12.21 -1.0%	$24.50 +100.7%	+67.4%	$914.17M	$125.58M	N/A	280	Positive News
PHAR Pharming Group	3.0492 of 5 stars	$12.81 flat	$38.33 +199.2%	+22.7%	$904.36M	$376.13M	80.07	280	Positive News
MGTX MeiraGTx	3.3421 of 5 stars	$9.75 +1.7%	$25.83 +165.0%	+87.2%	$888.12M	$81.39M	N/A	300
AMPH Amphastar Pharmaceuticals	3.71 of 5 stars	$19.71 -1.9%	$24.00 +21.8%	-20.9%	$885.83M	$719.89M	11.87	1,976	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVXL) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Competitors

AVXL vs. XNCR, PHAR, MGTX, AMPH, and ETON

How does Anavex Life Sciences compare to Xencor?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Summary

How does Anavex Life Sciences compare to MeiraGTx?

Summary

How does Anavex Life Sciences compare to Amphastar Pharmaceuticals?

Summary

How does Anavex Life Sciences compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Competitors

AVXL vs. XNCR, PHAR, MGTX, AMPH, and ETON

How does Anavex Life Sciences compare to Xencor?

Which has preferable valuation and earnings, AVXL or XNCR?

Do analysts prefer AVXL or XNCR?

Do institutionals & insiders hold more shares of AVXL or XNCR?

Does the media favor AVXL or XNCR?

Which has more volatility & risk, AVXL or XNCR?

Is AVXL or XNCR more profitable?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Which has preferable earnings and valuation, AVXL or PHAR?

Do analysts recommend AVXL or PHAR?

Is AVXL or PHAR more profitable?

Do insiders & institutionals hold more shares of AVXL or PHAR?

Which has more risk & volatility, AVXL or PHAR?

Does the media prefer AVXL or PHAR?

Summary

How does Anavex Life Sciences compare to MeiraGTx?

Which has better earnings & valuation, MGTX or AVXL?

Which has more risk & volatility, MGTX or AVXL?

Does the media favor MGTX or AVXL?

Do analysts prefer MGTX or AVXL?

Do institutionals & insiders have more ownership in MGTX or AVXL?

Is MGTX or AVXL more profitable?

Summary

How does Anavex Life Sciences compare to Amphastar Pharmaceuticals?

Which has more risk & volatility, AMPH or AVXL?

Is AMPH or AVXL more profitable?

Which has higher valuation and earnings, AMPH or AVXL?

Do analysts recommend AMPH or AVXL?

Do insiders & institutionals believe in AMPH or AVXL?

Does the media favor AMPH or AVXL?

Summary

How does Anavex Life Sciences compare to Eton Pharmaceuticals?

Which has more volatility & risk, AVXL or ETON?

Do insiders and institutionals hold more shares of AVXL or ETON?

Is AVXL or ETON more profitable?

Which has better earnings & valuation, AVXL or ETON?

Do analysts prefer AVXL or ETON?

Does the media refer more to AVXL or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools